International Convention Against Doping in Sport
Adopted in Paris on 19 October 2005

Entered into force on 1 February 2007

The General Conference of the United Nations Educational, Scientific and Cultural Organization, hereinafter referred to as “UNESCO”, meeting in Paris, from 3 to 21 October 2005, at its 33rd session,

Considering that the aim of UNESCO is to contribute to peace and security by promoting collaboration among nations through education, science and culture,

Referring to existing international instruments relating to human rights,

Aware of resolution 58/5 adopted by the General Assembly of the United Nations on 3 November 2003, concerning sport as a means to promote education, health, development and peace, notably its paragraph 7,

Conscious that sport should play an important role in the protection of health, in moral, cultural and physical education and in promoting international understanding and peace,

Noting the need to encourage and coordinate international cooperation towards the elimination of doping in sport,

Concerned by the use of doping by athletes in sport and the consequences thereof for their health, the principle of fair play, the elimination of cheating and the future of sport,

Mindful that doping puts at risk the ethical principles and educational values embodied in the International Charter of Physical Education and Sport of UNESCO and in the Olympic Charter,

Recalling that the Anti-Doping Convention and its Additional Protocol adopted within the framework of the Council of Europe are the public international law tools which are at the origin of national anti-doping policies and of intergovernmental cooperation,
Recalling the recommendations on doping adopted by the second, third and fourth International Conferences of Ministers and Senior Officials Responsible for Physical Education and Sport organized by UNESCO at Moscow (1988), Punta del Este (1999) and Athens (2004) and 32 C/Resolution 9 adopted by the General Conference of UNESCO at its 32nd session (2003),

Bearing in mind the World Anti-Doping Code adopted by the World Anti-Doping Agency at the World Conference on Doping in Sport, Copenhagen, 5 March 2003, and the Copenhagen Declaration on Anti-Doping in Sport,

Mindful also of the influence that elite athletes have on youth,

Aware of the ongoing need to conduct and promote research with the objectives of improving detection of doping and better understanding of the factors affecting use in order for prevention strategies to be most effective,

Aware also of the importance of ongoing education of athletes, athlete support personnel and the community at large in preventing doping,

Mindful of the need to build the capacity of States Parties to implement anti-doping programmes,

Aware that public authorities and the organizations responsible for sport have complementary responsibilities to prevent and combat doping in sport, notably to ensure the proper conduct, on the basis of the principle of fair play, of sports events and to protect the health of those that take part in them,

Recognizing that these authorities and organizations must work together for these purposes, ensuring the highest degree of independence and transparency at all appropriate levels,

Determined to take further and stronger cooperative action aimed at the elimination of doping in sport,

Recognizing that the elimination of doping in sport is dependent in part upon progressive harmonization of anti-doping standards and practices in sport and cooperation at the national and global levels,
I. Scope

ARTICLE 1
Purpose of the Convention

The purpose of this Convention, within the framework of the strategy and programme of activities of UNESCO in the area of physical education and sport, is to promote the prevention of and the fight against doping in sport, with a view to its elimination.

ARTICLE 2
Definitions

These definitions are to be understood within the context of the World Anti-Doping Code. However, in case of conflict the provisions of the Convention will prevail.

For the purposes of this Convention:


2. “Anti-doping organization” means an entity that is responsible for adopting rules for initiating, implementing or enforcing any part of the doping control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other major event organizations that conduct testing at their events, the World Anti-Doping Agency, international federations and national anti-doping organizations.

3. “Anti-doping rule violation” in sport means one or more of the following:
   (a) the presence of a prohibited substance or its metabolites or markers in an athlete’s bodily specimen;
   (b) use or attempted use of a prohibited substance or a prohibited method;
   (c) refusing, or failing without compelling justification, to submit to sample collection after notification as authorized in applicable anti-doping rules or otherwise evading sample collection;
   (d) violation of applicable requirements regarding athlete availability for out-of-competition testing, including failure to provide required whereabouts information and missed tests which are declared based on reasonable rules;
   (e) tampering, or attempting to tamper, with any part of doping control;
(f) possession of prohibited substances or methods;
(g) trafficking in any prohibited substance or prohibited method;
(h) administration or attempted administration of a prohibited substance or prohibited method to any athlete, or assisting, encouraging, aiding, abetting, covering up or any other type of complicity involving an anti-doping rule violation or any attempted violation.

4. “Athlete” means, for the purposes of doping control, any person who participates in sport at the international or national level as defined by each national anti-doping organization and accepted by States Parties and any additional person who participates in a sport or event at a lower level accepted by States Parties. For the purposes of education and training programmes, “athlete” means any person who participates in sport under the authority of a sports organization.

5. “Athlete support personnel” means any coach, trainer, manager, agent, team staff, official, medical or paramedical personnel working with or treating athletes participating in or preparing for sports competition.


7. “Competition” means a single race, match, game or singular athletic contest.

8. “Doping control” means the process including test distribution planning, sample collection and handling, laboratory analysis, results management, hearings and appeals.


10. “Duly authorized doping control teams” means doping control teams operating under the authority of international or national anti-doping organizations.

11. “In-competition” testing means, for purposes of differentiating between in-competition and out-of-competition testing, unless provided otherwise in the rules of an international federation or other relevant anti-doping organization, a test where an athlete is selected for testing in connection with a specific competition.

12. “International Standard for Laboratories” means the standard which is attached as Appendix 2 to this Convention.

13. “International Standard for Testing” means the standard which is attached as Appendix 3 to this Convention.
14. “No advance notice” means a doping control which takes place with no advance warning to the athlete and where the athlete is continuously chaperoned from the moment of notification through sample provision.

15. “Olympic Movement” means all those who agree to be guided by the Olympic Charter and who recognize the authority of the International Olympic Committee, namely the international federations of sports on the programme of the Olympic Games, the National Olympic Committees, the Organizing Committees of the Olympic Games, athletes, judges and referees, associations and clubs, as well as all the organizations and institutions recognized by the International Olympic Committee.

16. “Out-of-competition” doping control means any doping control which is not conducted in competition.

17. “Prohibited List” means the list which appears in Annex I to this Convention identifying the prohibited substances and prohibited methods.

18. “Prohibited method” means any method so described on the Prohibited List, which appears in Annex I to this Convention.

19. “Prohibited substance” means any substance so described on the Prohibited List, which appears in Annex I to this Convention.

20. “Sports organization” means any organization that serves as the ruling body for an event for one or several sports.


22. “Testing” means the parts of the doping control process involving test distribution planning, sample collection, sample handling and sample transport to the laboratory.

23. “Therapeutic use exemption” means an exemption granted in accordance with Standards for Granting Therapeutic Use Exemptions.

24. “Use” means the application, ingestion, injection or consumption by any means whatsoever of any prohibited substance or prohibited method.


**ARTICLE 3**

**Means to achieve the purpose of the Convention**

In order to achieve the purpose of the Convention, States Parties undertake to:

(a) adopt appropriate measures at the national and international levels which are consistent with the principles of the Code;
(b) encourage all forms of international cooperation aimed at protecting athletes and ethics in sport and at sharing the results of research;

(c) foster international cooperation between States Parties and leading organizations in the fight against doping in sport, in particular with the World Anti-Doping Agency.

**ARTICLE 4**

**Relationship of the Convention to the Code**

1. In order to coordinate the implementation, at the national and international levels, of the fight against doping in sport, States Parties commit themselves to the principles of the Code as the basis for the measures provided for in Article 5 of this Convention. Nothing in this Convention prevents States Parties from adopting additional measures complementary to the Code.

2. The Code and the most current version of Appendices 2 and 3 are reproduced for information purposes and are not an integral part of this Convention. The Appendices as such do not create any binding obligations under international law for States Parties.

3. The Annexes are an integral part of this Convention.

**ARTICLE 5**

**Measures to achieve the objectives of the Convention**

In abiding by the obligations contained in this Convention, each State Party undertakes to adopt appropriate measures. Such measures may include legislation, regulation, policies or administrative practices.

**ARTICLE 6**

**Relationship to other international instruments**

This Convention shall not alter the rights and obligations of States Parties which arise from other agreements previously concluded and consistent with the object and purpose of this Convention. This does not affect the enjoyment by other States Parties of their rights or the performance of their obligations under this Convention.

**II. Anti-doping activities at the national level**

**ARTICLE 7**

**Domestic Coordination**

States Parties shall ensure the application of the present Convention, notably through domestic coordination. To meet their obligations under this Convention, States Parties may rely on anti-doping organizations as well as sports authorities and organizations.
ARTICLE 8
Restricting the availability and use in sport of prohibited substances and methods

1. States Parties shall, where appropriate, adopt measures to restrict the availability of prohibited substances and methods in order to restrict their use in sport by athletes, unless the use is based upon a therapeutic use exemption. These include measures against trafficking to athletes and, to this end, measures to control production, movement, importation, distribution and sale.

2. States Parties shall adopt, or encourage, where appropriate, the relevant entities within their jurisdictions to adopt measures to prevent and to restrict the use and possession of prohibited substances and methods by athletes in sport, unless the use is based upon a therapeutic use exemption.

3. No measures taken pursuant to this Convention will impede the availability for legitimate purposes of substances and methods otherwise prohibited or controlled in sport.

ARTICLE 9
Measures against athlete support personnel
States Parties shall themselves take measures or encourage sports organizations and anti-doping organizations to adopt measures, including sanctions or penalties, aimed at athlete support personnel who commit an anti-doping rule violation or other offence connected with doping in sport.

ARTICLE 10
Nutritional supplements
States Parties, where appropriate, shall encourage producers and distributors of nutritional supplements to establish best practices in the marketing and distribution of nutritional supplements, including information regarding their analytic composition and quality assurance.

ARTICLE 11
Financial measures
States Parties shall, where appropriate:
(a) provide funding within their respective budgets to support a national testing programme across all sports or assist sports organizations and anti-doping organizations in financing doping controls either by direct subsidies or grants, or by
recognizing the costs of such controls when determining the overall subsidies or grants to be awarded to those organizations;

(b) take steps to withhold sport-related financial support to individual athletes or athlete support personnel who have been suspended following an anti-doping rule violation, during the period of their suspension;

(c) withhold some or all financial or other sport-related support from any sports organization or anti-doping organization not in compliance with the Code or applicable anti-doping rules adopted pursuant to the Code.

ARTICLE 12
Measures to facilitate doping control
States Parties shall, where appropriate:

(a) encourage and facilitate the implementation by sports organizations and anti-doping organizations within their jurisdiction of doping controls in a manner consistent with the Code, including no-advance notice, out-of-competition and in-competition testing;

(b) encourage and facilitate the negotiation by sports organizations and anti-doping organizations of agreements permitting their members to be tested by duly authorized doping control teams from other countries;

(c) undertake to assist the sports organizations and anti-doping organizations within their jurisdiction in gaining access to an accredited doping control laboratory for the purposes of doping control analysis.

III. International cooperation
ARTICLE 13
Cooperation between anti-doping organizations and sports organizations
States Parties shall encourage cooperation between anti-doping organizations, public authorities and sports organizations within their jurisdiction and those within the jurisdiction of other States Parties in order to achieve, at the international level, the purpose of this Convention.

ARTICLE 14
Supporting the mission of the World Anti-Doping Agency
States Parties undertake to support the important mission of the World Anti-Doping Agency in the international fight against doping.

**ARTICLE 15**

**Equal funding of the World Anti-Doping Agency**

States Parties support the principle of equal funding of the World Anti-Doping Agency’s approved annual core budget by public authorities and the Olympic Movement.

**ARTICLE 16**

**International cooperation in doping control**

Recognizing that the fight against doping in sport can only be effective when athletes can be tested with no advance notice and samples can be transported in a timely manner to laboratories for analysis, States Parties shall, where appropriate and in accordance with domestic law and procedures:

(a) facilitate the task of the World Anti-Doping Agency and anti-doping organizations operating in compliance with the Code, subject to relevant host countries’ regulations, of conducting in- or out-of-competition doping controls on their athletes, whether on their territory or elsewhere;

(b) facilitate the timely movement of duly authorized doping control teams across borders when conducting doping control activities;

(c) cooperate to expedite the timely shipping or carrying across borders of samples in such a way as to maintain their security and integrity;

(d) assist in the international coordination of doping controls by various anti-doping organizations, and cooperate to this end with the World Anti-Doping Agency;

(e) promote cooperation between doping control laboratories within their jurisdiction and those within the jurisdiction of other States Parties. In particular, States Parties with accredited doping control laboratories should encourage laboratories within their jurisdiction to assist other States Parties in enabling them to acquire the experience, skills and techniques necessary to establish their own laboratories should they wish to do so;

(f) encourage and support reciprocal testing arrangements between designated anti-doping organizations, in conformity with the Code;

(g) mutually recognize the doping control procedures and test results management, including the sport sanctions thereof, of any anti-doping organization that are consistent with the Code.
ARTICLE 17
Voluntary Fund

1. A “Fund for the Elimination of Doping in Sport”, hereinafter referred to as “the Voluntary Fund”, is hereby established. The Voluntary Fund shall consist of funds-in-trust established in accordance with the Financial Regulations of UNESCO. All contributions by States Parties and other actors shall be voluntary.

2. The resources of the Voluntary Fund shall consist of:
   (a) contributions made by States Parties;
   (b) contributions, gifts or bequests which may be made by:
       (i) other States;
       (ii) organizations and programmes of the United Nations system, particularly the United Nations Development Programme, as well as other international organizations;
       (iii) public or private bodies or individuals;
   (c) any interest due on the resources of the Voluntary Fund;
   (d) funds raised through collections, and receipts from events organized for the benefit of the Voluntary Fund;
   (e) any other resources authorized by the Voluntary Fund’s regulations, to be drawn up by the Conference of Parties.

3. Contributions into the Voluntary Fund by States Parties shall not be considered to be a replacement for States Parties’ commitment to pay their share of the World Anti-Doping Agency’s annual budget.

ARTICLE 18
Use and governance of the Voluntary Fund

Resources in the Voluntary Fund shall be allocated by the Conference of Parties for the financing of activities approved by it, notably to assist States Parties in developing and implementing anti-doping programmes, in accordance with the provisions of this Convention, taking into consideration the goals of the World Anti-Doping Agency, and may serve to cover functioning costs of this Convention. No political, economic or other conditions may be attached to contributions made to the Voluntary Fund.

IV. Education and training

ARTICLE 19
General education and training principles
1. States Parties shall undertake, within their means, to support, devise or implement education and training programmes on anti-doping. For the sporting community in general, these programmes should aim to provide updated and accurate information on:
   (a) the harm of doping to the ethical values of sport;
   (b) the health consequences of doping.
2. For athletes and athlete support personnel, in particular in their initial training, education and training programmes should, in addition to the above, aim to provide updated and accurate information on:
   (a) doping control procedures;
   (b) athletes’ rights and responsibilities in regard to anti-doping, including information about the Code and the anti-doping policies of the relevant sports and anti-doping organizations. Such information shall include the consequences of committing an anti-doping rule violation;
   (c) the list of prohibited substances and methods and therapeutic use exemptions;
   (d) nutritional supplements.

**ARTICLE 20**

**Professional codes of conduct**

States Parties shall encourage relevant competent professional associations and institutions to develop and implement appropriate codes of conduct, good practice and ethics related to anti-doping in sport that are consistent with the Code.

**ARTICLE 21**

**Involvement of athletes and athlete support personnel**

States Parties shall promote and, within their means, support active participation by athletes and athlete support personnel in all facets of the anti-doping work of sports and other relevant organizations and encourage sports organizations within their jurisdiction to do likewise.

**ARTICLE 22**

**Sports organizations and ongoing education and training on anti-doping**

States Parties shall encourage sports organizations and anti-doping organizations to implement ongoing education and training programmes for all athletes and athlete support personnel on the subjects identified in Article 19.
Article 23
Cooperation in education and training
States Parties shall cooperate mutually and with the relevant organizations to share, where appropriate, information, expertise and experience on effective anti-doping programmes.

V. Research
ARTICLE 24
Promotion of research in anti-doping
States Parties undertake, within their means, to encourage and promote anti-doping research in cooperation with sports and other relevant organizations on:
(a) prevention, detection methods, behavioural and social aspects, and the health consequences of doping;
(b) ways and means of devising scientifically-based physiological and psychological training programmes respectful of the integrity of the person;
(c) the use of all emerging substances and methods resulting from scientific developments.

ARTICLE 25
Nature of anti-doping research
When promoting anti-doping research, as set out in Article 24, States Parties shall ensure that such research will:
(a) comply with internationally recognized ethical practices;
(b) avoid the administration to athletes of prohibited substances and methods;
(c) be undertaken only with adequate precautions in place to prevent the results of anti-doping research being misused and applied for doping.

ARTICLE 26
Sharing the results of anti-doping research
Subject to compliance with applicable national and international law, States Parties shall, where appropriate, share the results of available anti-doping research with other States Parties and the World Anti-Doping Agency.

ARTICLE 27
Sport science research
States Parties shall encourage:
VI. Monitoring of the Convention

ARTICLE 28

Conference of Parties

1. A Conference of Parties is hereby established. The Conference of Parties shall be the sovereign body of this Convention.
2. The Conference of Parties shall meet in ordinary session in principle every two years. It may meet in extraordinary session if it so decides or at the request of at least one third of the States Parties.
3. Each State Party shall have one vote at the Conference of Parties.

ARTICLE 29

Advisory organization and observers to the Conference of Parties

The World Anti-Doping Agency shall be invited as an advisory organization to the Conference of Parties. The International Olympic Committee, the International Paralympic Committee, the Council of Europe and the Intergovernmental Committee for Physical Education and Sport (CIGEPS) shall be invited as observers. The Conference of Parties may decide to invite other relevant organizations as observers.

ARTICLE 30

Functions of the Conference of Parties

1. Besides those set forth in other provisions of this Convention, the functions of the Conference of Parties shall be to:
   (a) promote the purpose of this Convention;
   (b) discuss the relationship with the World Anti-Doping Agency and study the mechanisms of funding of the Agency’s annual core budget. States non-Parties may be invited to the discussion;
   (c) adopt a plan for the use of the resources of the Voluntary Fund, in accordance with Article 18;
   (d) examine the reports submitted by States Parties in accordance with Article 31;
(e) examine, on an ongoing basis, the monitoring of compliance with this Convention in response to the development of anti-doping systems, in accordance with Article 31. Any monitoring mechanism or measure that goes beyond Article 31 shall be funded through the Voluntary Fund established under Article 17;

(f) examine draft amendments to this Convention for adoption;

(g) examine for approval, in accordance with Article 34 of the Convention, modifications to the Prohibited List and to the Standards for Granting Therapeutic Use Exemptions adopted by the World Anti-Doping Agency;

(h) define and implement cooperation between States Parties and the World Anti-Doping Agency within the framework of this Convention;

(i) request a report from the World Anti-Doping Agency on the implementation of the Code to each of its sessions for examination.

2. The Conference of Parties, in fulfilling its functions, may cooperate with other intergovernmental bodies.

**ARTICLE 31**

**National reports to the Conference of Parties**

States Parties shall forward every two years to the Conference of Parties through the Secretariat, in one of the official languages of UNESCO, all relevant information concerning measures taken by them for the purpose of complying with the provisions of this Convention.

**ARTICLE 32**

**Secretariat of the Conference of Parties**

1. The secretariat of the Conference of Parties shall be provided by the Director-General of UNESCO.

2. At the request of the Conference of Parties, the Director-General of UNESCO shall use to the fullest extent possible the services of the World Anti-Doping Agency on terms agreed upon by the Conference of Parties.

3. Functioning costs related to the Convention will be funded from the regular budget of UNESCO within existing resources at an appropriate level, the Voluntary Fund established under Article 17 or an appropriate combination thereof as determined every two years. The financing for the secretariat from the regular budget shall be done on a strictly minimal basis, it being understood that voluntary funding should also be provided to support the Convention.
4. The secretariat shall prepare the documentation of the Conference of Parties, as well as the draft agenda of its meetings, and shall ensure the implementation of its decisions.

**ARTICLE 33**

**Amendments**

1. Each State Party may, by written communication addressed to the Director-General of UNESCO, propose amendments to this Convention. The Director-General shall circulate such communication to all States Parties. If, within six months from the date of the circulation of the communication, at least one half of the States Parties give their consent, the Director-General shall present such proposals to the following session of the Conference of Parties.

2. Amendments shall be adopted by the Conference of Parties with a two-thirds majority of States Parties present and voting.

3. Once adopted, amendments to this Convention shall be submitted for ratification, acceptance, approval or accession to States Parties.

4. With respect to the States Parties that have ratified, accepted, approved or acceded to them, amendments to this Convention shall enter into force three months after the deposit of the instruments referred to in paragraph 3 of this Article by two thirds of the States Parties. Thereafter, for each State Party that ratifies, accepts, approves or accedes to an amendment, the said amendment shall enter into force three months after the date of deposit by that State Party of its instrument of ratification, acceptance, approval or accession.

5. A State that becomes a Party to this Convention after the entry into force of amendments in conformity with paragraph 4 of this Article shall, failing an expression of different intention, be considered:
   (a) a Party to this Convention as so amended;
   (b) a Party to the unamended Convention in relation to any State Party not bound by the amendments.

**ARTICLE 34**

**Specific amendment procedure for the Annexes to the Convention**

1. If the World Anti-Doping Agency modifies the Prohibited List or the Standards for Granting Therapeutic Use Exemptions, it may, by written communication addressed to the Director-General of UNESCO, inform her/him of those changes. The Director-General shall notify such changes as proposed amendments to the relevant Annexes to
this Convention to all States Parties expeditiously. Amendments to the Annexes shall be approved by the Conference of Parties either at one of its sessions or through a written consultation.

2. States Parties have 45 days from the Director-General’s notification within which to express their objection to the proposed amendment either in writing, in case of written consultation, to the Director-General or at a session of the Conference of Parties. Unless two thirds of the States Parties express their objection, the proposed amendment shall be deemed to be approved by the Conference of Parties.

3. Amendments approved by the Conference of Parties shall be notified to States Parties by the Director-General. They shall enter into force 45 days after that notification, except for any State Party that has previously notified the Director-General that it does not accept these amendments.

4. A State Party having notified the Director-General that it does not accept an amendment approved according to the preceding paragraphs remains bound by the Annexes as not amended.

VII. Final clauses

ARTICLE 35

Federal or non-unitary constitutional systems

The following provisions shall apply to States Parties that have a federal or non-unitary constitutional system:

(a) with regard to the provisions of this Convention, the implementation of which comes under the legal jurisdiction of the federal or central legislative power, the obligations of the federal or central government shall be the same as for those States Parties which are not federal States;

(b) with regard to the provisions of this Convention, the implementation of which comes under the jurisdiction of individual constituent States, counties, provinces or cantons which are not obliged by the constitutional system of the federation to take legislative measures, the federal government shall inform the competent authorities of such States, counties, provinces or cantons of the said provisions, with its recommendation for their adoption.

ARTICLE 36

Ratification, acceptance, approval or accession
This Convention shall be subject to ratification, acceptance, approval or accession by Members States of UNESCO in accordance with their respective constitutional procedures. The instruments of ratification, acceptance, approval or accession shall be deposited with the Director-General of UNESCO.

ARTICLE 37

Entry into force

1. This Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of deposit of the thirtieth instrument of ratification, acceptance, approval or accession.

2. For any State that subsequently expresses its consent to be bound by it, the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of deposit of its instrument of ratification, acceptance, approval or accession.

ARTICLE 38

Territorial extension of the Convention

1. Any State may, when depositing its instrument of ratification, acceptance, approval or accession, specify the territory or territories for whose international relations it is responsible and to which this Convention shall apply.

2. Any State Party may, at any later date, by a declaration addressed to UNESCO, extend the application of this Convention to any other territory specified in the declaration. In respect of such territory the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of receipt of such declaration by the depositary.

3. Any declaration made under the two preceding paragraphs may, in respect of any territory specified in such declaration, be withdrawn by a notification addressed to UNESCO. Such withdrawal shall become effective on the first day of the month following the expiration of a period of one month after the date of receipt of such a notification by the depositary.

ARTICLE 39

Denunciation
Any State Party may denounce this Convention. The denunciation shall be notified by an instrument in writing, deposited with the Director-General of UNESCO. The denunciation shall take effect on the first day of the month following the expiration of a period of six months after the receipt of the instrument of denunciation. It shall in no way affect the financial obligations of the State Party concerned until the date on which the withdrawal takes effect.

**ARTICLE 40**

**Depositary**

The Director-General of UNESCO shall be the Depositary of this Convention and amendments thereto. As the Depositary, the Director-General of UNESCO shall inform the States Parties to this Convention, as well as the other States Members of the Organization of:

(a) the deposit of any instrument of ratification, acceptance, approval or accession;
(b) the date of entry into force of this Convention in accordance with Article 37;
(c) any report prepared in pursuance of the provisions of Article 31;
(d) any amendment to the Convention or to the Annexes adopted in accordance with Articles 33 and 34 and the date on which the amendment comes into force;
(e) any declaration or notification made under the provisions of Article 38;
(f) any notification made under the provisions of Article 39 and the date on which the denunciation takes effect;
(g) any other act, notification or communication relating to this Convention.

**ARTICLE 41**

**Registration**

In conformity with Article 102 of the Charter of the United Nations, this Convention shall be registered with the Secretariat of the United Nations at the request of the Director-General of UNESCO.

**ARTICLE 42**

**Authoritative texts**

1. This Convention, including its Annexes, has been drawn up in Arabic, Chinese, English, French, Russian and Spanish, the six texts being equally authoritative.
2. The Appendices to this Convention are provided in Arabic, Chinese, English, French, Russian and Spanish.
ARTICLE 43

Reservations

No reservations that are incompatible with the object and purpose of the present Convention shall be permitted.

Annexes I and II of the previous Command Paper for the Convention (Cm 6742, 2006) were those current from 1 January 2006. Annexes I and II on pages 25 to 40 of this Command Paper are the current annexes for the Convention updated on 1 January 2012 and 1 January 2011 respectively.

Annex I - The Prohibited List – International Standards
Annex II
Standards for Granting Therapeutic Use Exemptions

Appendix 1- World Anti-Doping Code
Appendix 2- International Standards for Laboratories
Appendix 3- International Standards for Testing

IN WITNESS WHEREOF the undersigned have signed this Convention this eighteen day of November 2005.
ANNEX I
THE 2012 PROHIBITED LIST
WORLD ANTI-DOPING CODE

Valid 1 January 2012
In accordance with Article 4.2.2 of the World Anti-Doping Code all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5 and S6(a) and Prohibited Methods M1, M2 and M3.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S0. NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, veterinary medicines) is prohibited at all times.

S1. ANABOLIC AGENTS
Anabolic agents are prohibited.

S1.1 Anabolic Androgenic Steroids (AAS)
(a) Exogenous* AAS, including:
1-androstenediol (5α-androst-1-ene-3β,17β-diol), 1-androstenedione (5α-androst-1-ene-3,17-dione), bolandiol (estr-4-ene-3β,17β-diol), bolasterone, boldenone, boldione (androsta-1,4-diene-3,17-dione), calusterone, clomestebol, danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole), dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one), desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol), drostanolone, ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone, formebolone, furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan), gestrinone, 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one), mestanolone, mesterolone,
metenolone, methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one), methandriol, methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol), methylidenolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one), methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one), methyl-nortestosterone (17β-hydroxy-17α-methylestr-4,9-dien-3-one), methyltestosterone, metribolone (methyltrirololone 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one), mibolerone, nandrolone, 19-norandrostenedione (estr-4-ene-3,17-dione), norboletone, norclostebol, norethandrolone, oxabolone, oxandrolone, oxymesterone, oxymetholone, prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole), quinbolone, stanozolol, stenbolone, 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one), tetrahydrogestrinone (18α-homo-pregna-4,9,11-trien-17β-ol-3-one), trenbolone, and other substances with a similar chemical structure or similar biological effect(s).

(b) Endogenous** AAS when administered exogenously:
Androstenediol (androst-5-ene-3β,17β-diol), androstenedione (androst-4-ene-3,17-dione), dihydrotestosterone (17β-hydroxy-5α-androstane-3-one), prasterone (dehydroepiandrosterone, DHEA), testosterone, and their metabolites and isomers, including but not limited to:

5α-androstane-3α,17α-diol, 5α-androstane-3α,17β-diol, 5α-androstane-3β,17α-diol, 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol, androst-4-ene-3α,17β-diol, androst-4-ene-3β,17α-diol, androst-4-ene-3β,17β-diol; androst-5-ene-3α,17α-diol, androst-5-ene-3α,17β-diol, androst-5-ene-3β,17α-diol, androst-5-ene-3β,17β-diol; androstenediol (androst-4-ene-3β,17β-diol), 5-androstenedione (androst-5-ene-3,17-dione), epi-dihydrotestosterone, epitestosterone, 3α-hydroxy-5α-androstane-17-one, 3β-hydroxy-5α-androstane-17-one, 7α-hydroxy-5α-androstane-17-one, 7β-hydroxy-DHEA, 7-keto-DHEA, 19-norandrosterone, 19-noretiocholanolone.

For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.

** “endogenous” refers to a substance which is capable of being produced by the body naturally.

S1.2 Other Anabolic Agents, including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES
The following substances and their releasing factors are prohibited:
1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)];
2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males;
3. Insulins;
4. Corticotrophins;
5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF), as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; and other substances with similar chemical structure or similar biological effect(s).

S3. BETA-2 AGONISTS
All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours), formoterol (maximum 36 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regime.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 30 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through
a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. HORMONE AND METABOLIC MODULATORS

The following are prohibited:

1. Aromatase inhibitors including, but not limited to: aminogluthethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone;

2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene;

3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant;

4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors;

5. Metabolic modulators: Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR).

S5. DIURETICS AND OTHER MASKING AGENTS

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol, intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid, and other substances with similar biological effect(s). Local application of felypressin in dental anaesthesia is not prohibited.

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and brinzolamide which are not prohibited).

The use In - and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use
Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

**PROHIBITED METHODS**

**M1. ENHANCEMENT OF OXYGEN TRANSFER**

The following are prohibited:

1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin;
2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.

**M2. CHEMICAL AND PHYSICAL MANIPULATION**

The following are prohibited:

1. *Tampering*, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control is prohibited. These include but are not limited to urine substitution and/or adulteration (e.g. proteases);
2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations;
3. Sequential withdrawal, manipulation and reintroduction of any quantity of whole blood into the circulatory system.

**M3. GENE DOPING**

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of nucleic acids or nucleic acid sequences;
2. The use of normal or genetically modified cells.
SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition:

PROHIBITED SUBSTANCES

S6. STIMULANTS

All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2012 Monitoring Program.*

Stimulants include:

(a) Non-Specified Stimulants:

Adrafinil, amfepramone, amiphenazole, amphetamine, amphetaminil, benfluorex, benzphetamine, benzylpiperazine, bromantan, clobenzorex, cocaine, cropropamide, crotetamide, dimethylamphetamine, etilamphetamine, famprofazone, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, mephentermine, mesocarb, methamphetamine(d-), p-methylamphetamine methylenedioxyamphetamine, methylenedioxymethamphetamine, modafinil, norfenfluramine, phendimetrazine, phenmetrazine, phentermine, 4-phenylpiracetam (carphedon), prenylamine, prolintane. A stimulant not expressly listed in this section is a Specified Substance.

(b) Specified Stimulants (examples):

Adrenaline **, cathine ***, ephedrine ****, etamivan, etilefrine, fenbutrazate, fencamfamin, heptaminol, isometheptene, levmetamfetamine, meclofenoxate, methylephedrine ****, methylhexaneamine (dimethylpentylamine), methylphenidate, nikethamide, norfenefrine, octopamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phenpromethamine, propylhexedrine, pseudoephedrine *****, selegiline, sibutramine, strychnine, tuaminoheptane, and other substances with a similar chemical structure or similar biological effect(s).
* The following substances included in the 2012 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as *Prohibited Substances*

** Local administration (e.g. nasal, ophthalmologic) of *Adrenaline* or coadministration with local anesthetic agents is not prohibited.

*** *Cathine* is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

**** Each of *ephedrine* and *methylephedrine* is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

****** *Pseudoephedrine* is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

S7. **NARCOTICS**

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. **CANNABINOIDS**

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics [e.g. “Spice” (containing JWH018, JWH073), HU-210) are prohibited.

S9. **GLUCOCORTICOSTEROIDS**

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1. ALCOHOL

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

- Aeronautic (FAI)
- Archery (FITA)
- Automobile (FIA)
- Karate (WKF)
- Motorcycling (FIM)
- Powerboating (UIM)

P2. BETA-BLOCKERS

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports:

- Aeronautic (FAI)
- Archery (FITA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Boules (CMSB)
- Bridge (FMB)
- Darts (WDF)
- Golf (IGF)
- Ninepin and Tenpin bowling (FIQ)
- Powerboating (UIM)
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air.

Beta-blockers include, but are not limited to, the following:

- Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.
ANNEX II
Extract from the INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS, 1 January 2011 of the World Anti-Doping Agency (WADA)

PART TWO: STANDARDS FOR GRANTING THERAPEUTIC USE EXEMPTIONS

4.0 Criteria for Granting a Therapeutic Use Exemption

A Therapeutic Use Exemption (TUE) may be granted to an Athlete permitting the Use of a Prohibited Substance or Prohibited Method. An application for a TUE will be reviewed by a Therapeutic Use Exemption Committee (TUEC). The TUEC will be appointed by an Anti-Doping Organization.

4.1 A TUE will be granted only in strict accordance with the following criteria:

(a) The Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method were to be withheld in the course of treating an acute or chronic medical condition.

(b) The Therapeutic Use of the Prohibited Substance or Prohibited Method would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. The Use of any Prohibited Substance or Prohibited Method to increase “low-normal” levels of any endogenous hormone is not considered an acceptable Therapeutic intervention.

(c) There is no reasonable Therapeutic alternative to the Use of the otherwise Prohibited Substance or Prohibited Method.

(d) The necessity for the Use of the otherwise Prohibited Substance or Prohibited Method cannot be a consequence, wholly or in part, of the prior Use, without a TUE, of a substance or method which was prohibited at the time of Use.

4.2 The TUE will be cancelled, if:

(a) The Athlete does not promptly comply with any requirements or conditions imposed by the Anti-Doping Organization granting the exemption.

(b) The term for which the TUE was granted has expired.
(c) The Athlete is advised that the **TUE** has been withdrawn by the Anti-Doping Organization.

(d) A decision granting a **TUE** has been reversed by WADA or the Court of Arbitration for Sport.

*Comment: Each **TUE** will have a specified duration as decided upon by the **TUEC**. There may be cases when a **TUE** has expired or has been withdrawn and the Prohibited Substance subject to the **TUE** is still present in the Athlete’s body. In such cases, the Anti-Doping Organization conducting the initial review of an Adverse Analytical Finding will consider whether the finding is consistent with expiry or withdrawal of the **TUE**.*

4.3 An application for a **TUE** will not be considered for retroactive approval except in cases where:

(a) Emergency treatment or treatment of an acute medical condition was necessary.

(b) Due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a **TUEC** to consider, an application prior to Doping Control.

*Comment: Medical emergencies or acute medical situations requiring administration of an otherwise Prohibited Substance or Prohibited Method before an application for a **TUE** can be made, are uncommon. Similarly, circumstances requiring expedited consideration of an application for a **TUE** due to imminent competition are infrequent. Anti-Doping Organizations granting **TUEs** should have internal procedures that permit such situations to be addressed.*

5.0. **Confidentiality of Information**

5.1 The collection, storage, processing, disclosure and retention of **Personal Information** in the **TUE** process by Anti-Doping Organizations and WADA shall comply with the **International Standard** for the Protection of Privacy and **Personal Information**.

5.2 An **Athlete** applying for a **TUE** shall provide written consent for the transmission of all information pertaining to the application to members of all **TUECs** with authority under the **Code** to review the file and, as required, other independent medical or scientific experts, and to all necessary staff involved in the management, review or appeal of **TUEs**, and WADA.
applicant shall also provide written consent for the decision of the TUEC to be distributed to other relevant Anti-Doping Organizations and National Federations under the provisions of the Code.

[Comment to 5.2: Prior to collecting Personal Information or obtaining consent from an Athlete, the Anti-Doping Organization shall communicate to the Athlete the information set forth in Article 7.1 of the International Standard for the Protection of Privacy and Personal Information.]

Should the assistance of external, independent experts be required, all details of the application will be circulated without identifying the Athlete concerned.

5.3 The members of the TUECs, independent experts and the staff of the Anti-Doping Organization involved, will conduct all of their activities in strict confidence and will sign confidentiality agreements. In particular, they will keep the following information confidential:

(a) All medical information and data provided by the Athlete and physician(s) involved in the Athlete’s care.
(b) All details of the application including the name of the physician(s) involved in the process.

Should the Athlete wish to revoke the right of any TUEC to obtain any health information on his/her behalf, the Athlete shall notify his/her medical practitioner in writing of the fact. As a consequence of such a decision, the Athlete will not receive approval for a TUE or renewal of an existing TUE.

5.4 Anti-Doping Organizations shall ensure that Personal Information obtained in the TUE process is retained for a period of eight (8) years, and thereafter only for as long as necessary to fulfill their obligations under the Code or where otherwise required by applicable law, regulation or compulsory legal process.

6.0 Therapeutic Use Exemption Committees (TUECs)

TUECs shall be constituted and act in accordance with the following guidelines:

6.1 TUECs should include at least three (3) physicians with experience in the care and treatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. In order to ensure a level of independence of decisions, the majority of the members of any TUEC should be free of conflicts of
interest or political responsibility in the *Anti- Doping Organization*. All members of a *TUEC* will sign a conflict of interest agreement. In applications involving *Athletes* with disabilities, at least one *TUEC* member shall possess specific experience with the care and treatment of *Athletes* with disabilities.

6.2 *TUECs* may seek whatever medical or scientific expertise they deem appropriate in reviewing the circumstances of any application for a *TUE*. 
6.3 The WADA TUEC shall be composed following the criteria set out in Article 6.1. The WADA TUEC is established to review the granting or denial of TUEs for International-Level Athletes, Athletes entered in an International Event as described under 7.1(b), or Athletes in their National Anti-Doping Organization’s Registered Testing Pool as set forth in Article 4.4 of the Code. In normal circumstances, the WADA TUEC shall render a decision within thirty (30) days of receipt of all requested information.

7.0 Responsibilities of International Federations and National Anti-Doping Organizations

7.1 Each International Federation shall:

(a) Establish a TUEC as provided in Article 6.

(b) Publish a list of International Events for which a TUE, granted pursuant to the International Federation’s rules, is required.

(c) Establish and publish a TUE process whereby any Athlete who is in the International Federation’s Registered Testing Pool or who is entered in an International Event described in Article 7.1(b) may request a TUE for a documented medical condition requiring the Use of a Prohibited Substance or a Prohibited Method. Such a TUE process shall comply with Article 4.4 of the Code, this International Standard and the International Standard for the Protection of Privacy and Personal Information.

(d) Publish any rule pursuant to which the International Federation will accept TUEs granted by other Anti-Doping Organizations.

(e) Promptly report to WADA, through ADAMS, the granting of all TUEs, including the approved substance or method, dosage, frequency and route of administration, the duration of the TUE, any conditions imposed in connection with the TUE, and its entire file.

(f) Promptly report the granting of a TUE to the relevant National Anti-Doping Organization and National Federation.

(g) At WADA’s request, promptly provide its entire file on any TUE which has been denied.

7.2 Each National Anti-Doping Organization shall:

(a) Establish a TUEC as provided in Article 6.
(b) Identify and publish those categories of Athletes within its jurisdiction who are required to obtain a TUE before using a Prohibited Substance or a Prohibited Method. At a minimum, this shall include all Athletes in the National Anti-Doping Organization’s Registered Testing Pool and other national-level Athletes as defined by the National Anti-Doping Organization.

[Comment to 7.2(b): National Anti-Doping Organizations will not grant TUEs to Athletes in an International Federation’s Registered Testing Pool except in those instances where the International Federation’s rules recognize or give authority to National Anti-Doping Organizations to grant TUEs to such Athletes.]

c) Establish and publish a TUE process whereby any Athlete who is in the National Anti-Doping Organization’s Registered Testing Pool or who is described in 7.2(b) may request a TUE for a documented medical condition requiring the Use of a Prohibited Substance or a Prohibited Method. Such a TUE process shall comply with Article 4.4 of the Code, this International Standard and the International Standard for the Protection of Privacy and Personal Information.

d) Promptly report to WADA, through ADAMS, the granting of a TUE to any Athlete in its Registered Testing Pool, and if applicable, to an Athlete in an International Federation’s Registered Testing Pool or entered in an International Event described in Article 7.1(b), including the approved substance or method, dosage, frequency and route of administration, the duration of the TUE, any conditions imposed in connection with the TUE, and its entire file.

e) At WADA’s request, promptly provide its entire file on any TUE that has been denied.

(f) Promptly report the granting of a TUE to the relevant National Federation and International Federation where the rules of the International Federation authorize National Anti-Doping Organizations to grant TUEs to International-Level Athletes.

g) Recognize TUEs granted by International Federations to Athletes in the International Federation’s Registered Testing Pool or entered in an International Event as described under 7.1(b).

[As used in this Article 7, the term "publish" means: An Anti-Doping Organization shall publish information by providing the information in a conspicuous place on its website and by sending the information to each National Federation which is subject to its rules.]
8.0 **TUE Application Process**

8.1 Unless the rules of their International Federation provide otherwise, the following *Athletes* shall obtain a *TUE* from their International Federation:

(a) *Athletes* in the International Federation’s *Registered Testing Pool*.

(b) *Athletes* participating in an *International Event* for which a *TUE*, granted pursuant to the International Federation’s rules, is required.

8.2 *Athletes* not identified in Article 8.1 shall obtain a *TUE* from their *National Anti-Doping Organization*.

[Comment to 8.1 and 8.2: Unless the rules of an International Federation provide otherwise, an Athlete who already has a *TUE* from a National Anti-Doping Organization, but later becomes a member of the International Federation’s Registered Testing Pool or seeks to participate in an International Event which the International Federation has identified as requiring an International Federation *TUE*, shall obtain a new *TUE* from the International Federation.

The phrase “unless the rules of an International Federation provide otherwise” takes into account the fact that some International Federations, through their rules, are willing to recognize *TUEs* granted by National Anti-Doping Organizations and do not require a new *TUE* application at the International Federation level. Where such rules are in place, the Athlete should obtain a *TUE* from the Athlete’s National Anti-Doping Organization.]

8.3 The *Athlete* should submit an application for a *TUE* no less than thirty (30) days before he/she needs the approval (for instance, for an *Event*).

8.4 A *TUE* will only be considered following the receipt of a completed application form that shall include all relevant documents (see Annex 1 – *TUE* Form). The application process shall be dealt with in accordance with the principles of strict medical confidentiality.

8.5 The *TUE* application Form, as set out in Annex 1, can be modified by Anti-Doping Organizations to include additional requests for information, but no sections or items shall be removed.

8.6 The *TUE* application Form may be translated into other languages by Anti-Doping Organizations, but the English or French text shall remain on the application Form.

8.7 The application shall identify the *Athlete*’s level of competition (e.g., International Federation’s *Registered Testing Pool*), sport and, where appropriate, discipline and specific position or role.
8.8 The application shall list any previous and/or current TUE requests, the body to whom the request(s) was made, the decision(s) of that body, and the decision(s) of any other body on review or appeal.

8.9 The application shall include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. The arguments related to the diagnosis and treatment, as well as duration of validity, should be guided by the WADA “Medical Information to Support the Decisions of TUECs.”

8.10 Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the Anti-Doping Organization before approval will be undertaken at the expense of the applicant.

[Comment to 8.10: In some cases, the applicant’s National Federation may elect to pay this expense.]

8.11 The application shall include a statement by an appropriately qualified physician attesting to the necessity of the otherwise Prohibited Substance or Prohibited Method in the treatment of the Athlete and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.

8.12 The substance or method, dose, frequency, route and duration of administration of the otherwise Prohibited Substance or Prohibited Method in question shall be specified. In case of change, a new application shall be submitted.

8.13 In normal circumstances, decisions of the TUEC should be completed within thirty (30) days of receipt of all relevant documentation and will be conveyed in writing to the Athlete by the relevant Anti-Doping Organization. In case of a TUE application made in a reasonable time limit prior to an Event the TUEC should use its best endeavors to complete the TUE process before the start of the Event.

[Comment to 8.13: When an Anti-Doping Organization has failed to act on an Athlete’s TUE application within a reasonable time, the Athlete may seek review by WADA as if the application was denied.]

9.0 Declaration of Use

9.1 There are no longer substances or methods on the Prohibited List that require a Declaration of Use and therefore it is not necessary to file a Declaration of Use.
10.0 Review of TUE Decisions by WADA

10.1 The WADA TUEC may, at any time, review the granting of a TUE to an Athlete in the International Federation’s Registered Testing Pool, entered in an International Event as described in 7.1(b), or a National Anti-Doping Organization’s Registered Testing Pool. In addition to the information to be provided as set forth in Articles 7.1 and 7.2, the WADA TUEC may also seek additional information from the Athlete, including further studies as described in Article 8.10. If a decision granting a TUE is reversed by WADA upon review, the reversal shall not apply retroactively and shall not disqualify the Athlete's results during the period for which the TUE had been granted and shall take effect no later than fourteen (14) days following notification of the decision to the Athlete.

10.2 An Athlete in an International Federation’s Registered Testing Pool, entered in an International Event as described in 7.1(b), or National Anti-Doping Organization’s Registered Testing Pool may request that WADA review the denial of a TUE by submitting a written request for review to WADA within twenty-one (21) days of the date of the denial. An Athlete submitting such a request for review to WADA shall pay an application fee as established by WADA and shall provide to the WADA TUEC copies of all information that the Athlete submitted to the Anti-Doping Organization in connection with the TUE application. The WADA TUEC will assess the request based on the file that was available to the Anti-Doping Organization that has denied the TUE but may, for the sake of clarification, seek additional information from the Athlete, including further studies as described in Article 8.10. Until the WADA review process has been completed, the original TUE denial remains in effect. If WADA reverses the denial of a TUE, the TUE shall immediately go into effect in accordance with the conditions set forth in the WADA decision.

10.3 Decisions by WADA to affirm or reverse the TUE decisions of an Anti-Doping Organization may be appealed to the Court of Arbitration for Sport as provided in Article 13 of the Code.

11.0 Previously Granted Abbreviated Therapeutic Use Exemptions

11.1 All previously granted Abbreviated Therapeutic Use Exemptions that have not already expired or been cancelled shall expire on December 31 2009.